AFFILIATIONS
1 Hospital Universitario de Salamanca, IBSAL, Madrid, Spain
2 Bristol Myers Squibb, Madrid, Spain
3 Bristol Myers Squibb, Madrid, Spain
4 Atrys Health, Madrid, Spain
5 Atrys Health, Madrid, Spain
6 Bristol Myers Squibb, Madrid, Spain
ABSTRACT
Introduction. In real-world clinical practice, the management of transfusion-dependent (TD) lower-risk myelodysplastic syndrome (LR-MDS) is influenced by age, comorbidities, and hematologic profile. Reducing transfusion burden (TB) remains a key unmet need. During the study period in Spain, the first-line (1L) therapies reimbursed by the Spanish National Health System (SNHS) for TD LR-MDS were erythropoiesis-stimulating agents (ESAs) and, in patients with del(5q), lenalidomide. Since September 2023, luspatercept has additionally been reimbursed for ring sideroblast-positive (RS+) patients who had failed prior ESA therapy; however, its broader, RS-independent 1L indication remains unreimbursed by the SNHS.
Objective. To characterize the epidemiology, baseline characteristics, TB, and therapeutic approach of these patients in routine clinical practice in Spain.
Methods. Retrospective multicenter observational study based on BIGPAC®, a clinical database which includes anonymized electronic health records from 6.5 million patients in the SNHS, encompassing primary care, hospital, and specialized care settings.
Patients ≥18 years with a diagnosis of LR-MDS (ICD-9/10 codes; risk-stratified by IPSS/IPSS-R) and TD (defined as ≥2 units of red blood cell [RBC] concentrates within 8 weeks) between 01/01/2021 and 31/05/2025 were included. TB was classified as low (<4 RBC units/8 weeks), moderate (4-5), or high (≥6). The index date (ID) was defined as the time at which both criteria were met. A minimum of 6 months of follow-up from ID was required for patient inclusion.
Baseline demographic, clinical, hematologic, and therapeutic variables were analyzed by 1L treatment, TB, and age.
Results. Among 2,614 adult patients with LR-MDS, 1,071 patients (41.0%) had TD, of whom 666 (62.2%) met the ≥6-month follow-up requirement and formed the cohort. Point prevalence of LR-MDS with TD as of 31/12/2025 was 10.57 cases per 100,000 individuals, and annual incidence rose from 3.95 cases per 100,000 person-years in 2021 to 5.02 in 2025.
Mean age was 77 years; 53.9% of patients were male, and 81.1% had ≥1 comorbidity, most frequently arterial hypertension (57.8%), dyslipidemia (45.5%), cardiovascular disease (32.3%), and diabetes mellitus (27.2%). Anemia was the predominant cytopenia (88.7%), and serum erythropoietin (EPO) levels were generally elevated (median: 220.48 mU/mL; IQR: 272.80). Among patients with available data, 30.8% were RS+ and 20.7% had SF3B1 mutations. TB was low in 26.0% of patients, moderate in 40.2%, and high in 33.8%; with high TB predominating in HMA (60.3%) and conservative (43.4%) groups.
During the study period, 34.2% of patients received ESAs (darbepoetin alfa and epoetin alfa/beta), 13.2% luspatercept, 8.9% lenalidomide, 8.7% hypomethylating agents (HMAs, azacitidine and decitabine), and 35.0% conservative management with transfusions as 1L therapy. Overall, median time from LR-MDS diagnosis to 1L treatment was 107 days (IQR: 151.75), but it was significantly longer among patients receiving luspatercept (532.00 days; IQR: 356.00) or HMAs (702.00 days; IQR: 556.50) (p < 0.001).
Baseline age and comorbidity burden differed significantly across 1L treatment groups (both p < 0.001). Older, more comorbid patients were concentrated in the luspatercept and conservative groups (mean age 79 and 82 years, respectively; median comorbidity burden 2.0 and 4.0 vs ~0.5 comorbidities in the remaining groups). Luspatercept patients had a higher proportion of SF3B1 mutations (51.1% vs 20.7% overall) and RS+ (75% vs 30.8% overall), together with elevated EPO (median: 388.21 mU/mL; IQR: 430.23) and ferritin levels (median: 1,730.98 ng/mL; IQR: 1,786.82).
Results regarding treatment duration, response, and impact will be presented at the congress.
Conclusions. In Spain, LR-MDS with TD shows increasing incidence and therapeutic heterogeneity, reflecting the need to optimize clinical management. Despite recent therapeutic advances, one-third of patients received RBC transfusions as their sole 1L treatment instead of active treatment, particularly older and more comorbid individuals. The clinical profile observed among luspatercept-treated patients, enriched for RS+ and SF3B1 mutations, along with the markedly delayed treatment initiation, likely reflects Spain's reimbursement criteria during the study period. Off-label treatment use and reimbursement criteria should be considered when interpreting real-world comparative outcomes.
DISCLOSURES
Maria Diez-Campelo, MD, PhD: Keros Therapeutics - Honoraria; Bristol Myers Squibb - Honoraria; AbbVie - Honoraria; GlaxoSmithKline - Honoraria; Novartis - Honoraria; Takeda - Research Funding; Bristol Myers Squibb - Research Funding; Otsuka Pharmaceutical - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Astex - Consultancy (Includes expert testimony); Curis Inc - Consultancy (Includes expert testimony); Geron Corporation - Consultancy (Includes expert testimony); Keros Therapeutics - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Syros Pharmaceuticals - Consultancy (Includes expert testimony); Roivant-Hemavant - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Fortrea - Consultancy (Includes expert testimony); Ascentage Pharma - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony)